GLMD has been the topic of a number of other reports. Canaccord Genuity Group downgraded Galmed Pharmaceuticals from a buy rating to a hold rating in a research note on Monday, August 8th. Cantor Fitzgerald downgraded Galmed Pharmaceuticals from an overweight rating to a neutral rating in a research note on Thursday, August 4th. Finally, Maxim Group downgraded Galmed Pharmaceuticals from a buy rating to a hold rating in a research note on Monday, August 8th. One equities research analyst has rated the stock with a sell rating and five have assigned a hold rating to the stock. According to MarketBeat, the stock has a consensus rating of Hold and a consensus target price of $5.00.
Galmed Pharmaceuticals Stock Down 6.2 %
Shares of Galmed Pharmaceuticals stock opened at $0.30 on Monday. The firm has a market cap of $7.55 million, a price-to-earnings ratio of -0.33 and a beta of 1.51. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.07 and a quick ratio of 4.07. Galmed Pharmaceuticals has a 52-week low of $0.30 and a 52-week high of $2.73. The stock has a 50-day simple moving average of $0.36 and a 200-day simple moving average of $0.46.
Institutional Inflows and Outflows
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
- Get a free copy of the StockNews.com research report on Galmed Pharmaceuticals (GLMD)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.